The Prostate · 2004 · 56 citations · 20 references
MedicineImmunologyOncologyAutoimmunityCancer ImmunologyMolecular OncologyAntibody CharacterizationCancer BiomarkersImmuno-oncology BiomarkersProstate CancerTumor AntigensTumor-associated AntigensHigh-sensitivity AssaysHumoral Immune Response AlterationsImmune MarkersImmunodiagnostic AssaysImmunodiagnostic BiomarkersProstate Tumor MarkersProstatic Immune ResponseSerum Biomarkers
BACKGROUND: Cytoplasmic p90 autoantigen was recently cloned from a cDNA expression library using serum antibody from a cancer patient. The humoral immune response to p90 in prostate cancer and benign prostatic hyperplasia (BPH) was examined. METHODS: An antigenic fragment of recombinant p90 protein and several other tumor-associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls. RESULTS: Autoantibodies to p90 were detected in 30.8% of 133 prostate cancer patients versus 1.5% in 68 BPH patients. When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. Antibodies to p90 showed the highest frequency in prostate cancer (30.8%), followed by antibodies to p62 (22.6%). CONCLUSIONS: A panel of six selected TAAs was shown to have high sensitivity and specificity as immunodiagnostic markers in prostate cancer.
20
The polycomb group protein EZH2 is involved in progression of prostate cancer
Sooryanarayana Varambally, Saravana M. Dhanasekaran, Ming Zhou et al. · Nature · 2002 · 2.7K citations · Full text